Examining outcomes in patients with relapsed/refractory multiple myeloma treated with T-cell redirectors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to describe the clinical outcomes of patients with relapsed/refractory multiple myeloma (RRMM) who have been treated with T-cell redirectors, specifically teclistamab and talquetamab, outside of clinical trials. It includes patients who received these treatments at various times, allowing for a comprehensive analysis of their effectiveness and safety in real-world settings. The study will gather data on patient responses and outcomes to better understand the impact of these therapies on RRMM.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Have a documented diagnosis of multiple myeloma
* Received the first dose of teclistamab on or before 31 December 2022, regardless of the duration of teclistamab treatment (REALiTEC cohort 1) OR Received the first dose of teclistamab from 01 January 2023 to 31 December 2024, inclusive, regardless of the duration of teclistamab treatment (REALiTEC cohort 2) OR Received the first dose of teclistamab from 01 January 2025 to 31 December 2025, inclusive, regardless of the duration of teclistamab treatment (REALiTEC cohort 3) OR Received the first dose of talquetamab on or before 31 December 2023, regardless of the duration of talquetamab treatment (REALiTAL cohort). Participants who received both teclistamab \& talquetamab can be included in both REALiTEC and REALiTAL cohorts
* Received at least one dose of teclistamab/talquetamab
* Provision of a patient-signed informed consent form (ICF), or an ICF waiver for deceased patients as applicable based on country/site-specific requirements

Exclusion Criteria:

* To be excluded from REALiTEC cohorts if received teclistamab as part of an interventional clinical trial
* To be excluded from REALiTAL cohort if received talquetamab as part of an interventional clinical trial
* Participants who have received teclistamab as part of a Janssen pre-approval access program are excluded from the REALiTEC Cohort 2 and REALiTEC Cohort 3

Where it's running

• Aalborg Sygehus Syd
  Aalborg, Denmark Recruiting
• Sygehus Lillebælt, Vejle
  Vejle, Denmark Recruiting
• Hopital Albert Calmette - CHU Lille
  Lille, France Recruiting
• CHU de Nantes hotel Dieu
  Nantes, France Recruiting
• Institut Universitaire du Cancer Toulouse Oncopole
  Toulouse, France Recruiting
• University Hospital Hamburg Eppendorf
  Hamburg, Germany Recruiting

+18 more sites. See ClinicalTrials.gov for the full list.

Study contacts

• Study coordinator: Study Contact
• Email: Participate-In-This-Study1@its.jnj.com
• Phone: 844-434-4210

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Linvoseltamab with pre-dose Tocilizumab to reduce CRS in adults with relapsed/refractory multiple myeloma

  This study tests whether giving tocilizumab before the first dose of linvoseltamab can lower the risk of cytokine release syndrome in adults with relapsed/refractory multiple myeloma who have had at least four prior therapies.

  Recruiting at 7 sites Phase 4 Regeneron Pharmaceuticals · Los Angeles, California and 6 other locations · NCT07609940

• Epunamin plus DECP for relapsed or refractory multiple myeloma

  This will test whether adding Epunamin to a DECP chemotherapy regimen helps people with relapsed or refractory multiple myeloma have better treatment responses.

  Recruiting Shanxi Bethune Hospital · Taiyuan, Shanxi · NCT07497165

• IASO206 injection for relapsed or refractory multiple myeloma

  A single-arm early study is testing IASO206 injection to see if it is safe and tolerable for adults with relapsed or refractory multiple myeloma who have tried at least two prior therapies.

  Recruiting Early Phase 1 Institute of Hematology & Blood Diseases Hospital, China · Tianjin · NCT07322159

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.